← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Thermo Fisher Scientific TMO $249B	2,575	+26	+1%	$208B
2	2 Danaher DHR $158B	2,279	+98	+4%	$159B
3	3 Regeneron Pharmaceuticals REGN $80.1B	1,392	+57	+4%	$97.5B
4	4 Novartis NVS $279B	1,313	+5	+0.4%	$15.2B
5	5 Agilent Technologies A $49.1B	1,052	+39	+4%	$37.2B
6	6 Illumina ILMN $41B	806	+31	+4%	$18.6B
7	7 Charles River Laboratories CRL $14.4B	629	-37	-6%	$10.3B
8	8 Alnylam Pharmaceuticals ALNY $30B	567	+44	+8%	$34.1B
9	9 Revvity RVTY $17B	527	+41	+8%	$13.9B
10	10 DELISTED CATALENT, INC. CTLT	470	+22	+5%	$10.8B
11	11 Sarepta Therapeutics SRPT $1.78B	458	-27	-6%	$10.8B
12	12 CRISPR Therapeutics CRSP $4.86B	416	-33	-7%	$2.81B
13	13 Bruker BRKR $8.47B	367	+2	+0.5%	$8.01B
14	14 Ionis Pharmaceuticals IONS $7.1B	354	-3	-0.8%	$6.3B
15	15 Qiagen QGEN $9.41B	331	+25	+8%	$7.05B
16	16 Azenta AZTA $1.63B	313	-9	-3%	$2.41B
17	17 GRAIL Inc GRAL $6.24B	311	-61	-16%	$281M
18	18 Ultragenyx Pharmaceutical RARE $1.47B	301	+26	+9%	$4.82B
19	19 Veracyte VCYT $3.5B	292	+52	+22%	$2.78B
20	20 Intellia Therapeutics NTLA $1.6B	284	-7	-2%	$1.92B
21	21 Krystal Biotech KRYS $9.79B	283	+38	+16%	$5.15B
22	22 Arrowhead Research ARWR $8.25B	271	-1	-0.4%	$1.89B
23	23 Guardant Health GH $21.9B	271	-11	-4%	$2.86B
24	24 Vericel Corp VCEL $2.06B	268	+7	+3%	$2.15B
25	25 10x Genomics TXG $9.52B	266	+5	+2%	$2.36B